M
1.05
0.00 (-0.02%)
| Previous Close | 1.05 |
| Open | 1.04 |
| Volume | 55,117 |
| Avg. Volume (3M) | 495,403 |
| Market Cap | 9,011,421 |
| 52 Weeks Range | |
| Earnings Date | 1 Apr 2025 |
| Operating Margin (TTM) | -2,307.21% |
| Diluted EPS (TTM) | -22.36 |
| Quarterly Revenue Growth (YOY) | -13.10% |
| Total Debt/Equity (MRQ) | 54.10% |
| Current Ratio (MRQ) | 1.32 |
| Operating Cash Flow (TTM) | -17.09 M |
| Levered Free Cash Flow (TTM) | -10.45 M |
| Return on Assets (TTM) | -80.37% |
| Return on Equity (TTM) | -465.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Mainz Biomed N.V. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.8 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | -2.1 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.12 |
Select this tab to load the latest available analysis.
|
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 6.13% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |